Discovery of a ‘cheat code’ for CAR‑T manufacturing: Creating more potent cancer‑cell assassins by inhibiting BCL‑2
1. The challenge of CAR‑T therapy: generating non‑exhausted T cells
CAR‑T (Chimeric Antigen Receptor T‑cell) therapy, which engineers a patient’s T cells to attack cancer cells, has achieved remarkable results in hematologic malignancies. However, a major issue remains: during large‑scale ex‑vivo expansion, T cells rapidly become exhausted or lose functional activity, limiting their efficacy once infused into patients.
2. Venetoclax repurposed: a death‑inhibitor becomes a stamina enhancer
The investigators focused on Venetoclax, an anti‑cancer drug that targets the anti‑apoptotic protein BCL‑2. Although traditionally used to kill cancer cells, precise administration of Venetoclax during the CAR‑T manufacturing phase produced an unexpected outcome: instead of inducing T‑cell death, it re‑programmed the cells into ‘super‑CAR‑T’ with markedly enhanced cytotoxicity against tumor cells.
3. Cellular ‘re‑wiring’ that enhances energy efficiency
This transformation occurs because Venetoclax remodels intracellular signaling and metabolic pathways in T cells. It activates key growth signals such as IL‑2/STAT5 and PI3K/AKT, and optimizes mitochondrial oxidative phosphorylation (OXPHOS). Consequently, CAR‑T cells acquire the ability to sustain potent anti‑tumor activity over extended periods while consuming less energy.
4. Implications and future outlook
The study demonstrates that BH3‑mimetic agents such as Venetoclax can serve not only as cytotoxic drugs but also as precise modulators of immune cells. If this approach is incorporated into standard CAR‑T manufacturing, it could offer markedly stronger and more durable therapeutic options for patients who have failed conventional therapies or experienced disease relapse.
Targeting the BCL-2 family of proteins, key regulators of cellular apoptosis, with BH3-mimetics has been a major therapeutic goal to overcome cancer cell death resistance. However, beyond their canonical roles in apoptosis, BCL-2 proteins also play vital roles in cellular metabolism, signaling, and, increasingly, immune cell regulation. T cells in particular depend heavily on BCL-2 family proteins during ontogeny and maintenance, yet the broader consequences of pharmacologically inhibiting anti-apoptotic BCL-2 proteins in T cells remain underexplored. Our group has previously demonstrated that BCL-2 inhibition with the BH3-mimetic venetoclax induces gene expression and plasticity changes in murine T cells. Building upon this, we here investigate whether venetoclax-driven T cell reprogramming can be leveraged to enhance adoptive cell therapies, specifically using chimeric antigen receptor (CAR) T cells targeting CD19 as a model system. Our findings reveal that venetoclax treatment during ex vivo expansion of CART cells, prepared from T cells from healthy donors or chemotherapeutically pretreated patients, potently augments antitumor efficacy in a BCL-2-dependent manner. Transcriptomic and functional analyses demonstrate that venetoclax reprograms CART cells by regulating signaling pathways (e.g., IL-2/STAT5 and PI3K/AKT) and metabolic programs (e.g., OXPHOS and glycolysis), yielding CART cells with superior fitness and effector functionalities. These results highlight a novel therapeutic approach using anti-apoptotic drugging to enhance the performance of adoptive T cell therapies and support further examination of venetoclax and other BH3-mimetics as immune modulators.
It opens a pathway to overcome the fundamental limitation in which cells become weakened during manufacturing, leading to therapeutic failure, by using a single drug. By producing more robust and long‑lasting CAR‑T cells for infusion, the approach could dramatically increase the likelihood that patients with advanced hematologic malignancies achieve durable remission.